We want to know the most common polymorphism of β adrenergic receptor gene associated with bisoprolol therapy in heart failure studies. We want replicate in our population.
-Yu WP, Lou M, Deng B, Song HM, Wang HB (2006) Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 34: 776–780.WP YuM. LouB. DengHM SongHB Wang2006Beta1-adrenergic receptor (Arg389Gly) polymorphism and response to bisoprolol in patients with chronic heart failure.Zhonghua Xin Xue Guan Bing Za Zhi34776780
-Terra SG, Hamilton KK, Pauly DF, Lee CR, Patterson JH, et al. (2005) Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics 15: 227–234.
-de Groote P, Helbecque N, Lamblin N, Hermant X, Mc Fadden E, et al. (2005) Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenet Genomics 15: 137–142.
-.Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, et al. (2003) Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9: 1300–1305.
Article An evaluation of the beta-1 adrenergic receptor Arg389Gly po...
Article β1 Adrenergic Receptor Polymorphisms and Heart Failure: A Me...
Article β-adrenergic receptor polymorphisms in susceptibility, respo...
Article Impact of the β-1 adrenergic receptor polymorphism on tolera...
I can not answer your question, yet may I suggest that you get familiar with the essentially different effect of low dose and high dose ß-blocker therapy. Since there are two families of myocardial lamellar orientation, the transmural one being much more ensitive to ß-blockers than the tangential one, you get qite a different reaction to low-dose therapy than to high dose therapy.